Sandro Wealth Management LLC Invests $1.96 Million in Roivant Sciences Ltd. $ROIV

Key Points

• Sandro Wealth Management LLC opened a new position in Roivant Sciences (NASDAQ:ROIV), purchasing 90,267 shares valued at approximately $1.96 million, which represents 1.6% of its portfolio and its 20th largest holding.
• Insiders sold a total of 5,085,398 shares worth about $139.2 million in the last quarter (including large sales by Director Melissa Epperly and CAO Jennifer Humes), though insiders still own 10.8% of the company.
• Analysts have a consensus rating of Moderate Buy (10 Buys, 1 Hold, 1 Sell) with an average target price of $30.55; ROIV trades near $27.83 and has a market cap of roughly $19.9 billion.

Sandro Wealth Management LLC purchased a new position in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 90,267 shares of the company's stock, valued at approximately $1,959,000. Roivant Sciences comprises 1.6% of Sandro Wealth Management LLC's portfolio, making the stock its 20th biggest holding.

A number of other hedge funds have also modified their holdings of the stock. Bessemer Group Inc. increased its stake in shares of Roivant Sciences by 41.5% in the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company's stock worth $28,000 after acquiring an additional 543 shares during the last quarter. Allworth Financial LP increased its stake in shares of Roivant Sciences by 48.1% in the third quarter. Allworth Financial LP now owns 1,795 shares of the company's stock worth $27,000 after acquiring an additional 583 shares during the last quarter. Fifth Third Bancorp increased its stake in shares of Roivant Sciences by 15.8% in the fourth quarter. Fifth Third Bancorp now owns 4,310 shares of the company's stock worth $94,000 after acquiring an additional 588 shares during the last quarter. Utah Retirement Systems increased its stake in shares of Roivant Sciences by 3.0% in the third quarter. Utah Retirement Systems now owns 20,626 shares of the company's stock worth $312,000 after acquiring an additional 600 shares during the last quarter. Finally, Xponance Inc. increased its stake in shares of Roivant Sciences by 1.9% in the third quarter. Xponance Inc. now owns 46,718 shares of the company's stock worth $707,000 after acquiring an additional 882 shares during the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.

Roivant Sciences Stock Performance

Shares of NASDAQ:ROIV opened at $27.83 on Friday. The company has a market cap of $19.92 billion, a P/E ratio of -23.79 and a beta of 1.14. The stock's 50-day moving average is $28.30 and its 200-day moving average is $23.90. Roivant Sciences Ltd. has a 52-week low of $10.58 and a 52-week high of $30.33.

Insider Buying and Selling

In other news, Director Melissa B. Epperly sold 41,861 shares of the firm's stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $28.68, for a total value of $1,200,573.48. Following the sale, the director directly owned 15,804 shares of the company's stock, valued at approximately $453,258.72. This trade represents a 72.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Jennifer Humes sold 13,538 shares of the firm's stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $28.37, for a total value of $384,073.06. Following the completion of the sale, the chief accounting officer directly owned 84,191 shares in the company, valued at approximately $2,388,498.67. This represents a 13.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 5,085,398 shares of company stock valued at $139,215,946 in the last quarter. Insiders own 10.80% of the company's stock.

Wall Street Analysts Forecast Growth

ROIV has been the topic of several analyst reports. TD Cowen reissued a "buy" rating on shares of Roivant Sciences in a research report on Wednesday, March 4th. Guggenheim increased their target price on shares of Roivant Sciences from $28.00 to $30.00 and gave the stock a "buy" rating in a research report on Monday, February 9th. HC Wainwright increased their target price on shares of Roivant Sciences from $33.00 to $34.00 and gave the stock a "buy" rating in a research report on Wednesday, March 4th. Jefferies Financial Group reissued a "buy" rating on shares of Roivant Sciences in a research report on Tuesday, March 3rd. Finally, Weiss Ratings downgraded shares of Roivant Sciences from a "hold (c-)" rating to a "sell (d)" rating in a research report on Monday, February 9th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $30.55.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

Want to see what other hedge funds are holding ROIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.